These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Randomized trials of closure of persistent foramen ovale (PFO) vs medical therapy for patients with cryptogenic stroke - Effect of lost-to-follow-up and withdrawal of consent. Dellborg M; Eriksson P Int J Cardiol; 2016 Mar; 207():308-9. PubMed ID: 26814634 [No Abstract] [Full Text] [Related]
25. Patent foramen ovale closure with GORE HELEX or CARDIOFORM Septal Occluder vs. antiplatelet therapy for reduction of recurrent stroke or new brain infarct in patients with prior cryptogenic stroke: Design of the randomized Gore REDUCE Clinical Study. Kasner SE; Thomassen L; Søndergaard L; Rhodes JF; Larsen CC; Jacobson J Int J Stroke; 2017 Dec; 12(9):998-1004. PubMed ID: 29090661 [TBL] [Abstract][Full Text] [Related]
26. Current Dataset for Patent Foramen Ovale Closure in Cryptogenic Stroke: Randomized Clinical Trials and Observational Studies. Odunukan OW; Price MJ Interv Cardiol Clin; 2017 Oct; 6(4):525-538. PubMed ID: 28886843 [TBL] [Abstract][Full Text] [Related]
33. Patent Foramen Ovale and Cryptogenic Stroke or Transient Ischemic Attack: To Close or Not to Close? A Systematic Review and Meta-Analysis. Lattanzi S; Brigo F; Cagnetti C; Di Napoli M; Silvestrini M Cerebrovasc Dis; 2018; 45(5-6):193-203. PubMed ID: 29649819 [TBL] [Abstract][Full Text] [Related]
34. Patent Foramen Ovale Closure for Secondary Prevention of Cryptogenic Stroke: Updated Meta-Analysis of Randomized Clinical Trials. Vaduganathan M; Qamar A; Gupta A; Bajaj N; Golwala HB; Pandey A; Bhatt DL Am J Med; 2018 May; 131(5):575-577. PubMed ID: 29229471 [TBL] [Abstract][Full Text] [Related]
35. Cryptogenic Strokes and Patent Foramen Ovales: What's the Right Treatment? Dalen JE; Alpert JS Am J Med; 2016 Nov; 129(11):1159-1162. PubMed ID: 27566504 [TBL] [Abstract][Full Text] [Related]
37. Risk of cerebrovascular events in patients with patent foramen ovale and intracardiac devices. Poddar KL; Nagarajan V; Krishnaswamy A; Bajaj NS; Kumari M; Bdair H; Modi D; Agarwal S; Goel SS; Parashar A; Tuzcu EM; Kapadia SR JACC Cardiovasc Interv; 2014 Nov; 7(11):1221-6. PubMed ID: 25326741 [TBL] [Abstract][Full Text] [Related]
38. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials. A science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. O'Gara PT; Messe SR; Tuzcu EM; Catha G; Ring JC; ; ; J Am Coll Cardiol; 2009 May; 53(21):2014-8. PubMed ID: 19460622 [TBL] [Abstract][Full Text] [Related]
39. Percutaneous device closure of patent foramen ovale for secondary stroke prevention: a call for completion of randomized clinical trials: a science advisory from the American Heart Association/American Stroke Association and the American College of Cardiology Foundation. O'Gara PT; Messe SR; Tuzcu EM; Catha G; Ring JC; ; ; Circulation; 2009 May; 119(20):2743-7. PubMed ID: 19433754 [TBL] [Abstract][Full Text] [Related]
40. Long-term outcomes of patent foramen ovale closure or medical therapy after cryptogenic stroke: A meta-analysis of randomized trials. Abdelaziz HK; Saad M; Abuomara HZ; Nairooz R; Pothineni NVK; Madmani ME; Roberts DH; Mahmud E Catheter Cardiovasc Interv; 2018 Jul; 92(1):176-186. PubMed ID: 29726616 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]